Conjugate of PAMAM Dendrimer, Doxorubicin and Monoclonal Antibody—Trastuzumab: The New Approach of a Well-Known Strategy

Conjugate of PAMAM Dendrimer, Doxorubicin and Monoclonal Antibody—Trastuzumab: The New Approach of a Well-Known Strategy

The strategy utilizing trastuzumab, a humanized monoclonal antibody against human epidermal growth receptor 2 (HER-2), as a therapeutic agent in HER-2 positive breast cancer therapy seems to have advantage over traditional chemotherapy, especially when given in combination with anticancer drugs. How...

Full description

Bibliographic Details
Main Authors: Monika Marcinkowska, Ewelina Sobierajska, Maciej Stanczyk, Anna Janaszewska, Arkadiusz Chworos, Barbara Klajnert-Maculewicz
Format: Article
Language:English
Published: MDPI AG 2018-02-01
Series:Polymers
Subjects:
PAMAM dendrimer
trastuzumab
HER-2
doxorubicin
tumor targeting
Online Access:http://www.mdpi.com/2073-4360/10/2/187

Internet

http://www.mdpi.com/2073-4360/10/2/187

Similar Items